Cargando…

Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway

When early prophase PtK(1) or Indian muntjac cells are exposed to topoisomerase II (topo II) inhibitors that induce little if any DNA damage, they are delayed from entering mitosis. We show that this delay is overridden by inhibiting the p38, but not the ATM, kinase. Treating early prophase cells wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikhailov, Alexei, Shinohara, Mio, Rieder, Conly L.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2004
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172207/ https://www.ncbi.nlm.nih.gov/pubmed/15302851 http://dx.doi.org/10.1083/jcb.200405167

Ejemplares similares

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

MAPK-triggered chromatin reprogramming by histone deacetylase in plant innate immunity
por: Latrasse, David, et al.
Publicado: (2017)

P38 Mitogen-activated Protein Kinase Activity Is Required during Mitosis for Timely Satisfaction of the Mitotic Checkpoint But Not for the Fidelity of Chromosome Segregation
por: Lee, Kyunghee, et al.
Publicado: (2010)

Entry into Mitosis in Vertebrate Somatic Cells Is Guarded by a Chromosome Damage Checkpoint That Reverses the Cell Cycle When Triggered during Early but Not Late Prophase
por: Rieder, Conly L., et al.
Publicado: (1998)

The nature of cell-cycle checkpoints: facts and fallacies
por: Khodjakov, Alexey, et al.
Publicado: (2009)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling
por: Choi, Sin Young, et al.
Publicado: (2016)

Histone deacetylase-4 and histone deacetylase-8 regulate interleukin-1β-induced cartilage catabolic degradation through MAPK/JNK and ERK pathways
por: Wang, Pengcheng, et al.
Publicado: (2018)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies
por: Dent, Paul, et al.
Publicado: (2019)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Direct Monitoring of the Strand Passage Reaction of DNA Topoisomerase II Triggers Checkpoint Activation
por: Furniss, Katherine L., et al.
Publicado: (2013)

Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells
por: Lee, Kyunghee, et al.
Publicado: (2011)

Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function
por: Bhat, Sajad A., et al.
Publicado: (2018)

Histone Deacetylase Inhibitors Trichostatin A and MCP30 Relieve Benzene-Induced Hematotoxicity via Restoring Topoisomerase IIα
por: Chen, Jingjing, et al.
Publicado: (2016)

Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity
por: Huang, Yahui, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied
por: Brito, Daniela A., et al.
Publicado: (2008)

Prognostic biomarker MCP-4 triggers epithelial-mesenchymal transition via the p38 MAPK pathway in ovarian cancer
por: Li, Siting, et al.
Publicado: (2022)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2012)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Cells satisfy the mitotic checkpoint in Taxol, and do so faster in concentrations that stabilize syntelic attachments
por: Yang, Zhenye, et al.
Publicado: (2009)

Delaying histone deacetylase response to injury accelerates conversion into repair Schwann cells and nerve regeneration
por: Brügger, Valérie, et al.
Publicado: (2017)

Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype
por: Lecce, Laura, et al.
Publicado: (2021)

Regulation of endothelial-to-mesenchymal transition by histone deacetylase 3 posttranslational modifications in neointimal hyperplasia
por: Chen, Lifang, et al.
Publicado: (2023)

Targeting DNA topoisomerases or checkpoint kinases results in an overload of chaperone systems, triggering aggregation of a metastable subproteome
por: Huiting, Wouter, et al.
Publicado: (2022)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_bvpcrmjhsd53fhc0vmomqkomdc